This section covers weight loss and weight management in the United States — obesity research, treatment options, dietary interventions and the scientific and cultural conversations around body weight. Reporting follows the evidence and avoids individualized advice.
Two Phase 3 trials of Eli Lilly's experimental drug produced large weight reductions and relief from knee osteoarthritis pain in more than 1,000 adults.
Live Poll
Would you consider a weight-loss drug if it could also ease your joint pain?
November 8, 2026
Trump Comments on Hinson's Body at Iowa RallyThe president described Rep. Ashley Hinson's weight loss during a Dubuque speech supporting her Senate campaign.
November 8, 2026
Jenna Jameson Shares Weight Loss After Quitting KetoThe 52-year-old posted before-and-after Instagram images and set a new goal of 115 pounds.
November 7, 2026
Semaglutide Shows Weight Loss Gains in Liver DiseaseNovo Nordisk reports real-world data on semaglutide 2.4 mg in adults with MASH, presented at a Denver liver conference.
November 6, 2026
FDA Warns on Unapproved Compounded GLP-1 DrugsThe agency says compounded semaglutide and tirzepatide products are not reviewed for safety, effectiveness, or quality before sale.
November 6, 2026
Trump Lashes Out at Reuters Reporter on TarmacTrump confronted a Reuters correspondent over a question about cancelling a Kansas rally, then campaigned for Roger Marshall days later.
November 6, 2026
WW Beats Estimates as Subscribers DeclineWW International reported third-quarter 2026 earnings of $1.51 per share, above the 66-cent Wall Street estimate, even as revenue fell 11.2%.
November 6, 2026
GLP-1 Use Surges Among Non-Diabetic AdultsA Northwestern study finds use of GLP-1 receptor agonists grew sharply from 2017 to 2022 while out-of-pocket costs fell for patients.
November 4, 2026
Kailera Reports Third Quarter 2026 ResultsThe clinical-stage obesity biotech posted a net loss of $95.7 million and advanced several weight-loss programs through 2026.
November 4, 2026
Sironax to Present Obesity Drug Data at ObesityWeekThe clinical-stage biotech will show two SIR4156 abstracts in poster sessions at the Obesity Society's annual meeting in November.
November 3, 2026
FDA Approves Monthly Olanzapine Shot for SchizophreniaThe once-monthly subcutaneous formulation, sold as Weltruza, is approved for adults with schizophrenia.
Obesity prevalence data and its public health implications, GLP-1 and other weight loss drug clinical results and approvals, surgical intervention outcomes, diet and behavioral research findings, and the cultural and body image conversations that intersect with clinical weight management are the recurring subjects here. New York, Los Angeles, Chicago, Houston and Phoenix are among the metropolitan areas where obesity rates, health system capacity to treat it and the media and cultural conversations surrounding weight are most intensively covered. GLP-1 drug approvals and their expanding clinical applications have generated the most sustained and highest-volume coverage surge in this area in recent years, touching clinical, economic, cultural and policy dimensions simultaneously. Access and affordability for weight management treatments — including both medications and surgical options — produce a recurring coverage thread tied to insurance coverage, drug pricing and the distribution of health resources across income levels.
